A nitrogen-containing heterocyclic α-carbonylthioamide compound and its preparation method and application

By developing α-carbonylthioamide compounds containing nitrogen heterocycles, the side effects of existing anti-osteoclast drugs have been solved, effective inhibition of RANKL-induced osteoclast differentiation, and a safe and effective therapeutic solution New drugs for bone diseases.

CN118666760BActive Publication Date: 2024-11-08ZHEJIANG UNIV CITY COLLEGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411166502.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-08
Estimated Expiration
2044-08-23

AI Technical Summary

Technical Problem

Existing anti-osteoclastic drugs such as bisphosphonates and desulumab have side effects during long-term use, such as mandibular osteonecrosis, atypical femoral fractures and reduced bone density, resulting in a clinically safe and effective novel anti-clinical There is an urgent need for osteoclast drugs.

Method used

Develop an α-carbonylthioamide compound containing heterocyclic ring, with a specific structure of 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazine- 1-yl)phenyl)-2-oxoethioamide, the compound is prepared by a specific synthetic route and used in osteoclast differentiation inhibitors.

Benefits of technology

This compound significantly inhibits RANKL-induced osteoclast differentiation without significant cytotoxicity, providing a safe and effective new drug option for the treatment of osteolytic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118666760B_ABST
    Figure CN118666760B_ABST
Patent Text Reader

Abstract

The present invention discloses a nitrogen-containing heterocyclic α-carbonylthioamide compound, a preparation method and an application thereof. The present invention uses 1-chloro-4-nitrobenzene as a starting material to prepare 2-(4-chlorophenyl)- N 2-(4-(4-(5-fluoropyrimidine-2-yl)piperazine-1-yl)phenyl)-2-oxoethylthioamide. The present invention provides 2-(4-chlorophenyl)- N Cell experiments have shown that ‑(4‑(4‑(5‑fluoropyrimidin‑2‑yl)piperazine‑1‑yl)phenyl)‑2‑oxoethylthioamide has a significant inhibitory effect on RANKL-induced osteoclast differentiation without obvious cytotoxicity. It can be used as a novel candidate drug for inhibiting osteoclast differentiation and for the treatment of osteolytic diseases caused by excessive osteoclast activation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of compound preparation, and specifically relates to a nitrogen-containing heterocyclic α-carbonylthioamide compound and a preparation method thereof, as well as an application of the compound in the preparation of an osteoclast differentiation inhibitor. Background Art

[0002] Osteoclasts (OCs) are the only cells in the body that have the function of bone resorption. They are differentiated from hematopoietic monocytes / macrophages under the induction of receptor activator of nuclear kappa B ligand (RANKL). Differentiated and mature osteoclasts secrete acidic substances to dissolve minerals in bones and secrete proteases to digest their organic matrix components, thus playing an important physiological role in bone development and homeostasis maintenance. However, under the influence of pathological factors such as estrogen deficiency, elevated inflammatory factors, and tumor cell bone metastasis, osteoclasts will be overproduced and activated in the body, leading to osteolytic diseases such as postmenopausal osteoporosis, inflammatory bone destruction (such as rheumatoid arthritis, periodontitis), and tumor metastasis bone destruction.

[0003] Since osteoclasts play a key driving role in osteolytic diseases, inhibiting the formation of osteoclasts is one of the main strategies for treating such diseases. Currently, the anti-osteoclast drugs used in clinical practice mainly include bisphosphonates and denosumab (anti-RANKL monoclonal antibody). However, these drugs have certain side effects. For example, long-term use of bisphosphonates and denosumab may cause side effects such as mandibular osteonecrosis and atypical femoral fractures, and once denosumab is discontinued, it will also cause a rapid decrease in the patient's bone density and increase the risk of vertebral fractures. Therefore, there is an urgent need to develop safe and effective new anti-osteoclast-related drugs to meet the clinical demand for such drugs. Summary of the invention

[0004] In view of this, the embodiments of the present application provide a nitrogen-containing heterocyclic α-carbonylthioamide compound and a preparation method and application thereof.

[0005] According to an embodiment of the present application, a nitrogen-containing heterocyclic α-carbonylthioamide compound is provided, and its structural formula is shown in formula (1):

[0006]

[0007] The chemical formula name of this compound is 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide.

[0008] The preparation method of the above-mentioned nitrogen-containing heterocyclic α-carbonylthioamide compound is achieved by the following synthetic route:

[0009]

[0010] The preparation method of the above-mentioned 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoethanethioamide comprises the following steps:

[0011] (1) 1-Chloro-4-nitrobenzene and piperazine react at high temperature in diethylene glycol dimethyl ether to generate 1-(4-nitrophenyl)piperazine (compound 1);

[0012] (2) 1-(4-nitrophenyl)piperazine and 2-chloro-5-fluoropyrimidine react at high temperature under potassium carbonate catalysis to generate 5-fluoro-2-(4-(4-nitrophenyl)piperazin-1-yl)pyrimidine (compound 2);

[0013] (3) 5-Fluoro-2-(4-(4-nitrophenyl)piperazin-1-yl)pyrimidine was reduced with hydrogen under palladium-carbon catalysis to generate 4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)aniline (Compound 3) at room temperature;

[0014] (4) 4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)aniline is oxidized under potassium peroxosulfate complex conditions to generate 5-fluoro-2-(4-(4-nitrosophenyl)piperazin-1-yl)pyrimidine (Compound 4);

[0015] (5) 5-Fluoro-2-(4-(4-nitrosophenyl)piperazin-1-yl)pyrimidine, 1-(4-chlorophenyl)-2-(dimethyl-L4-sulfinyl)ethan-1-one and thioacetic acid were reacted with ammonium carbonate as the catalyst to generate the target compound 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide (Compound 5).

[0016] Specifically, the preparation method may include the following steps:

[0017] (1) Add the compounds 1-chloro-4-nitrobenzene and piperazine to a reaction flask, disperse them in diethylene glycol dimethyl ether, and heat the system to a high temperature for reaction. After TLC shows that the reaction is complete, cool the system, add water, stir, filter, wash the filter cake with water and petroleum ether in turn, and vacuum dry the obtained solid to obtain the product 1-(4-nitrophenyl)piperazine;

[0018] (2) Add 1-(4-nitrophenyl)piperazine, 2-chloro-5-fluoropyrimidine and potassium carbonate to the reaction flask, disperse in diethylene glycol dimethyl ether, heat to high temperature and react overnight until the reaction is complete. Cool to room temperature, add water and stir, filter, wash with water and petroleum ether, and dry in vacuum to obtain the product 5-fluoro-2-(4-(4-nitrophenyl)piperazine-1-yl)pyrimidine;

[0019] (3) Add the compound 5-fluoro-2-(4-(4-nitrophenyl)piperazin-1-yl)pyrimidine to the reaction flask, dissolve it in methanol, and then add Pd / C. The reaction system is replaced with H2, and the reaction solution is stirred overnight under H2 atmosphere. TLC monitoring shows that the reaction is complete. Filter and concentrate the filtrate under reduced pressure. The crude product is purified by column to obtain 4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)aniline;

[0020] (4) 4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)aniline was dissolved in DCM, and an aqueous solution of potassium persulfate complex salt was added. The reaction was carried out at room temperature until the reaction was complete. DCM extraction was performed, and the organic phase was dried over anhydrous sodium sulfate and rotary evaporated to obtain a crude product. The product 5-fluoro-2-(4-(4-nitrosophenyl)piperazin-1-yl)pyrimidine was obtained by column chromatography;

[0021] (5) Add 1-(4-chlorophenyl)-2-(dimethyl-L4-sulfinyl)ethan-1-one to a sealed tube, add anhydrous acetonitrile and 5-fluoro-2-(4-(4-nitrosophenyl)piperazin-1-yl)pyrimidine, and react in an ice bath until the reaction is complete. Add thioacetic acid and ammonium carbonate and react until the reaction is complete. Pass through a column to obtain the final product 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide.

[0022] In the above technical solution, further, the high temperature described in (1) is 80-120°C;

[0023] Furthermore, the high temperature described in (2) is 60-100°C.

[0024] Furthermore, in (5), the molar ratio of 5-fluoro-2-(4-(4-nitrosophenyl)piperazin-1-yl)pyrimidine, 1-(4-chlorophenyl)-2-(dimethyl-L4-sulfinyl)ethan-1-one, and thioacetic acid is 1:1:(1.5~3).

[0025] Application of the above 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoethanethioamide in the preparation of osteoclast differentiation inhibitors.

[0026] The osteoclast differentiation inhibitor may be a drug for treating osteolytic diseases to inhibit the excessive activation of osteoclasts in osteolytic diseases; the osteoclast differentiation inhibitor may be a drug for treating postmenopausal osteoporosis, tumor metastasis bone destruction or inflammatory bone destruction.

[0027] The present invention has been confirmed by cell experiments: 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoethanethioamide has a significant inhibitory effect on RANKL-induced osteoclast differentiation and has no obvious cytotoxicity. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate embodiments consistent with the present application and, together with the description, serve to explain the principles of the present application.

[0029] Figure 1 This is the H NMR spectrum of 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide given in Example 1.

[0030] Figure 2 This is the carbon NMR spectrum of 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide given in Example 1.

[0031] Figure 3 The results are from an experiment using CCK-8 to detect the effect of 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide on the cell viability of mouse bone marrow mononuclear / macrophages (BMMs).

[0032] Figure 4The experimental results show that 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide affects RANKL-induced osteoclast differentiation of BMMs. A is a TRAP staining image, scale: 400 μm; B is a quantitative analysis of the number of osteoclasts. Control group: 15 ng / mL M-CSF treatment group; RANKL group: 15 ng / mL M-CSF and 100 ng / mL RANKL treatment group; 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide treatment group: 15 ng / mL M-CSF and 100 ng / mL RANKL treatment, and the indicated concentrations of 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide were added. Data are expressed as mean ± standard deviation. *: p <0.05, **: p <0.01; ***: p <0.001; ****: p <0.0001. DETAILED DESCRIPTION

[0033] The present invention will be further described below in conjunction with the examples and drawings. The following examples are only intended to illustrate the present invention, but are not intended to limit the present invention in any way.

[0034] Example 1 Preparation of 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide

[0035]

[0036] (1) Preparation of 1-(4-nitrophenyl)piperazine

[0037] 1-Chloro-4-nitrobenzene (10.0 g, 63.5 mmol) and piperazine (21.9 g, 254.2 mmol) were dissolved in a 250 mL round-bottom flask containing diethylene glycol dimethyl ether (23 mL), and the system was heated to 100 ° C for 4 hours. After the TLC plate showed that the reaction was complete, the reaction solution was cooled to about 50 ° C, 100 mL of water was added, and stirred at room temperature for 1 hour. The reaction solution was then filtered, and the filter cake was washed with water (20 mL, 3 times) and petroleum ether (20 mL, 3 times) in turn. The obtained solid was vacuum dried to obtain the product 1-(4-nitrophenyl)piperazine, with a yield of 95%.

[0038] (2) Preparation of 5-fluoro-2-(4-(4-nitrophenyl)piperazin-1-yl)pyrimidine

[0039] 1-(4-nitrophenyl)piperazine (12.0 g, 57.9 mmol), 2-chloro-5-fluoropyrimidine (7.8 g, 59.1 mmol) and potassium carbonate (16.2 g, 117.2 mmol) were dispersed in a 250 mL round-bottom flask containing diethylene glycol dimethyl ether (80 mL), and the system was heated to 100 ° C for overnight reaction until the TLC plate showed that the reaction was complete. After cooling to room temperature, 100 mL of water was added and stirred at room temperature for 1 hour. The reaction solution was then filtered, and the filter cake was washed with water (20 mL, 3 times) and petroleum ether (20 mL, 3 times) in turn. The obtained solid was vacuum dried to obtain the product 5-fluoro-2-(4-(4-nitrophenyl)piperazine-1-yl)pyrimidine with a yield of 88%.

[0040] (3) Preparation of 4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)aniline

[0041] 5-Fluoro-2-(4-(4-nitrophenyl)piperazin-1-yl)pyrimidine (12.1 g, 40.0 mmol) was dissolved in a 500 mL round-bottom flask containing methanol (200 mL), and then Pd / C was added. The reaction system was replaced with hydrogen three times, and the reaction solution was stirred overnight in a hydrogen atmosphere until TLC monitoring showed that the reaction was complete. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure and directly mixed with silica gel and passed through a column (ethyl acetate: petroleum ether, 0 to 10% gradient elution) to obtain 4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)aniline with a yield of 84%.

[0042] (4) Preparation of 5-fluoro-2-(4-(4-nitrosophenyl)piperazin-1-yl)pyrimidine

[0043] Dissolve 4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)aniline (8.2g, 30.0mmol) in a round-bottom flask filled with dichloromethane (100mL), slowly drop a solution of potassium peroxydisulfate (18.4g, 30.0mmol) in water (50mL), and stir at room temperature until the raw material reacts completely. Add water (20mL), let stand and separate, keep the organic phase, extract with dichloromethane (30mL, 2 times), combine the organic phases, dry over anhydrous sodium sulfate, and evaporate under reduced pressure to obtain a crude product. The crude product is mixed with silica gel and passed through a column (pure petroleum ether) to obtain 5-fluoro-2-(4-(4-nitrosophenyl)piperazine-1-yl)pyrimidine with a yield of 62%.

[0044] (5) Preparation of 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide

[0045] 1-(4-chlorophenyl)-2-(dimethyl-L4-sulfinyl)ethan-1-one (214.7 mg, 1.0 mmol) was placed in a 50 mL sealed tube, and anhydrous acetonitrile (5 mL) and 5-fluoro-2-(4-(4-nitrosophenyl)piperazin-1-yl)pyrimidine were added in sequence. The mixture was stirred for 1 hour under ice bath conditions until TLC monitoring showed that the raw material reaction was complete. Thioacetic acid (114.2 mg, 1.5 mmol) and ammonium carbonate (96.1 mg, 1.0 mmol) were then added to the system in sequence, and stirred for 2 hours at room temperature until the reaction was complete. After the solvent was removed by distillation under reduced pressure, the crude product was mixed with silica gel and passed through a column (petroleum ether: ethyl acetate = 8:1) to obtain a red solid product 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethylthioamide with a yield of 76%. The H NMR spectrum of the obtained product is shown in Figure 1 Its NMR carbon spectrum is shown as Figure 2 As shown, its structural formula is as follows:

[0046]

[0047] Melting point: 206.5-207.0℃.

[0048] 1 H NMR (400 MHz, CDCl3): δ 10.08 (s, 1H), 8.23 ​​– 8.21 (m, 2H), 8.04 (d, J = 8.2 Hz, 2H), 7.92 (d, J = 8.5 Hz, 2H), 7.42 (d, J = 8.3 Hz, 2H), 7.01 (d, J =8.1 Hz, 2H), 3.95 (t, J = 5.6 Hz, 4H), 3.32 (t, J = 4.4 Hz, 4H);

[0049] 13 C{ 1 H} NMR (100 MHz, DMSO): δ 191.8, 185.9, 158.9, 152.0 (d, J = 245.0Hz), 149.9, 146.0 (d, J= 22.0 Hz), 139.5, 132.5, 132.0, 130.4, 129.5, 123.7,115.7, 48.2, 44.2; 19F NMR (500 MHz, DMSO): δ -156.2. HRMS (ESI): m / z calcd for[M+H] + : 456.1056 and 458.1027, found: 456.1050 and 458.1022.

[0050] Example 2 (Activity Evaluation) Evaluation of 2-(4-chlorophenyl)- N Cytotoxicity of 4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide and its inhibitory effect on RANKL-induced osteoclast differentiation

[0051] The specific experiments are as follows:

[0052] Experiment 1: CCK-8 method was used to detect 2-(4-chlorophenyl)- N Cytotoxicity of 4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide on mouse bone marrow mononuclear macrophages (BMMs)

[0053] (1) Isolation and culture of primary mouse bone marrow-derived monocytes / macrophages (BMMs)

[0054] 8-10 week old C57BL / 6 mice were killed by cervical dislocation and then soaked in 75% medical alcohol for 3 minutes. The lower limbs of the mice were dissected in a clean bench, and the skin, fascia, and joint capsules of the knee and hip joints were separated. The femurs and tibias of the mice were obtained and placed in a culture dish with sterile DPBS (Dulbecco's Phosphate-Buffered Saline) added in advance. Use sterile scissors to cut the upper end of the femur and the lower end of the tibia, separate the bone marrow by instant centrifugation at 10,000 rpm, then add 10 mL of α-MEM complete culture medium (i.e., α-MEM culture medium containing 10% fetal bovine serum and 1% penicillin-streptomycin double antibody), gently pipet and mix, then transfer to a 10 cm sterile cell culture dish, and incubate in a 37°C, 5% CO2 incubator; on the second day, centrifuge to collect non-adherent cells, add BMMs growth culture medium (i.e., α-MEM complete culture medium containing 15 ng / mL M-CSF), gently pipet and mix, then transfer to a new sterile cell culture dish and culture overnight; on the second day, change the medium to remove non-adherent cells, and continue to culture until the cells grow to about 80%-90%, and these cells are considered primary bone marrow-derived monocytes / macrophages (BMMs).

[0055] (2) Digestion and counting of primary bone marrow-derived monocytes / macrophages

[0056] Discard the culture medium, wash twice with sterile DPBS, add 2 mL of trypsin for 4 minutes, then add complete culture medium containing α-MEM to terminate digestion, slowly and gently blow the cells and collect the culture medium, and centrifuge horizontally at room temperature (1000 rpm, 5 minutes). Discard the supernatant, add an appropriate amount of BMMs growth culture medium to resuspend the cells, and gently blow and mix; at the same time, take 100 μL of cell suspension to the EP tube, add 1900 μL of 0.4% trypan blue dye, observe under a microscope within 3 minutes, and count the number of cells in the 4 large grids of the counting plate that are not stained by the dye. The cell density of the above cell suspension is: (total number of cells in 4 large grids / 4) × dilution factor (20 times) × 10 4 / mL (Note: dead cells will be stained blue, live cells will not be stained).

[0057] (3) CCK-8 assay to detect the cytotoxicity of 2-(4-chlorophenyl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide on BMMs

[0058] BMMs were divided into 5×10 3 The cells were seeded into 96-well plates at a density of 1.54 μM / well. Six groups were set up in each plate, including a control group (only the drug solvent dimethyl sulfoxide was added) and five drug-added groups (adding 0.3125, 0.625, 1.25, 2.5, and 5 μM 2-(4-chlorophenyl)- N -(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoethylthioamide). Five replicate wells were set up in each group; the culture medium was BMMs growth medium (i.e., α-MEM complete culture medium containing 15 ng / mL M-CSF), and the culture was carried out for 24, 48, and 72 hours, respectively, and the medium was changed every other day. At the corresponding time point, 10 μL of CCK-8 reagent was added to each well, and the cells were incubated in a cell culture incubator for 1 hour under dark conditions, then taken out, fully shaken on an enzyme reader and the absorbance value at 450 nm was measured (the more active cells, the higher the absorbance). The experimental results showed that 2-(4-chlorophenyl)- N -(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide had no significant cytotoxicity to BMMs (see Figure 3 ).

[0059] Experiment 2: Tartrate-resistant acid phosphatase (TRAP) staining was used to assess the expression of 2-(4-chlorophenyl)- NEffect of -(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide on RANKL-induced osteoclast differentiation of BMMs

[0060] There were control group, RANKL induction group and 5 different concentrations of 2-(4-chlorophenyl)- N -(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide treatment group. BMMs were divided into 1×10 5 Cells were seeded at a density of 1.54 cells / well in a 24-well plate, cultured overnight in BMMs growth medium, and then treated as follows: the control group was treated with BMMs growth medium containing the same amount of DMSO as the drug-treated group (i.e., α-MEM complete medium containing 15 ng / mL M-CSF); the RANKL group was treated with osteoclast induction medium containing the same amount of DMSO as the drug-treated group (i.e., α-MEM complete medium containing 15 ng / mL M-CSF and 100 ng / mL RANKL); 0.3125, 0.625, 1.25, 2.5, and 5 μM 2-(4-chlorophenyl)- N The groups treated with 2-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide were added with 0.3125, 0.625, 1.25, 2.5, and 5 μM 2-(4-chlorophenyl)- N -(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoethanethioamide osteoclast induction medium. Each of the above groups had 3 replicate wells, and the medium was changed every other day. After 5 days of culture, the medium was aspirated, washed once with DPBS, and 4% paraformaldehyde 500 uL / well was added to fix the cells for 30 minutes. The kit was used for tartrate-resistant acid phosphatase staining, and the number of mature osteoclasts (i.e., cells with 5 or more nuclei, TRAP-positive staining, and giant morphology) was quantitatively counted under an inverted microscope to evaluate the 2-(4-chlorophenyl)- N -(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide effects on osteoclast differentiation. TRAP staining results showed that: 2-(4-chlorophenyl)- N -(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide dose-dependently inhibited RANKL-induced osteoclast differentiation, especially 5 μM 2-(4-chlorophenyl)- N There was basically no osteoclast formation in the group treated with -(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide (see Figure 4Quantitative results further showed that the number of osteoclasts in the 0.3125μM and 0.625μM drug treatment groups was not significantly different from that in the RANKL group, while the number of osteoclasts in the 1.25μM, 2.5μM and 5μM drug treatment groups was reduced by 29%, 78% and 93% respectively compared with that in the RANKL group (see Figure 4 Middle B).

[0061] The above are only some preferred embodiments of the present invention, which are used to help explain the present invention. The protection scope of the present invention is not limited to the above embodiments, but all technical solutions under the concept of the present invention belong to the protection scope of the present invention.

Claims

1. Use of a nitrogen-containing heterocyclic α-carbonylthioamide compound in the preparation of an osteoclast differentiation inhibitor, wherein the compound is represented by formula (1): ; The chemical formula name of this compound is 2-(4-chlorophenyl)- N -(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoethanethioamide.

2. The use according to claim 1, characterized in that: The nitrogen-containing heterocyclic α-carbonylthioamide compound is used for preparing medicine for treating osteolytic diseases.

3. The use according to claim 1, characterized in that: The nitrogen-containing heterocyclic alpha-carbonylthioamide compound is used for preparing medicine for treating postmenopausal osteoporosis, tumor metastasis bone destruction or inflammatory bone destruction.